短程化疗中乙肝病毒标志物阳性对肝功能影响及处理  

The impact of HBVM positive to hepatic function and relative countermeasure

作　　者：李进升 王福生 陈宇 

机构地区：[1]高州市慢性病防治站,广东525200

出　　处：《临床肺科杂志》2009年第5期628-629,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的探讨抗结核治疗中乙肝病毒感染对肝功能的影响及其对策。方法回顾性分析818例肺结核病人及其中150例药物性肝损害的相关临床资料。结果160例乙型肝炎病毒标志物(HBVM)阳性结核病人中有77例(48.1%)出现肝功能损害。HBVM阴性患者658例中出现肝损害73例(11.1%),HBVM阳性与阴性的肝损害发生率差异极显著(P<0.01)。结论抗结核治疗中HBVM阳性患者发生肝损比率明显增加,损害程度也明显增高,在抗结核治疗前检查HBVM及肝功能十分必要,之后密切监测肝功能的变化。Objective To explore the influence to hepatic function caused by liver virus infection of tuberculosis cases during chemical anti-tuberculosis treatment and relative countermeasure. Methods Retrospective analysis on the clinical data of 818 pulmonary tuberculosis cases （PTB） was conducted. There were evidences on liver function damaged in 150 eases. Results 77 cases （48.1%） out of 160 PTB suffered with HBVM positive were observed in damaged liver function. While 73 （11.1%） out of 658 suffered from HBVM negative. There was a significant difference （ P 〈 0. 01 ） of liver function damaged incidence between HBVM positive and negative PTB cases. Conclusion Due to the use of anti-tuberculosis treatment, the HBVM positive patients obviously has increased their chances of damaging their liver function. Testing HBVM and hepatic function is necessary before providing ant-tuberculosis treatment for the PTB eases. Close observation on the change of hepatic function should be taken.

关 键 词：结核 HBVM阳性 肝功能损害 

分 类 号：R521[医药卫生—内科学] R575[医药卫生—临床医学]